Skip to main content

Table 1 Inclusion and exclusion criteria

From: SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients

Inclusion criteria
• Age 18 years or older
• AKI requiring RRT (defined according to RIFLEa, AKINb or KDIGOc criteria)
• Expected to require RRT for at least 4 days with two (2) sampling sechedules
• Clinical indication for IV piperacillin-tazobactam, meropenem, imipenem-cilastatin, vancomycin or linezolid
• Presence of intra-arterial line for blood sampling if RRT filter port sampling not possible
• Informed consent from patient or patient’s authorised representative
Exclusion criteria
• Imminent death/patient not expected to survive
• Major bleeding or blood haemoglobin concentration <70 g/L or platelets <20 x 109/L
• Regular dosing with any of the 5 study antibiotics for greater than 36 h, within the 7 days prior to enrolment
• Unable to obtain consent
 
  1. aBellomo R et al. Crit Care 2004, 8:R204-R212 (DOI 10.1186/cc2872)
  2. bMetha RL et al. Crit Care 2007, 11:R31 (doi:10.1186/cc5713)
  3. cKidneyDisease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012, 2:1-138
  4. Abbreviations: AKI acute kidney injury, RRT renal replacement therapy, RIFLE Risk, Injury, Failure, Loss and End stage Renal Disease, AKIN Acute Kidney Injury Network, KDIGO Kidney Disease Improving Global Outcomes, IV intravenous